The role of mTOR inhibition as second-line therapy in metastatic renal carcinoma: clinical evidence and current challenges - González-Larriba J., Maroto P., Durán I., Lambea J., Flores L., Castellano D., Anido U., Basterrechea L., Casanovas O., Chirivella I., Climent M., Dur I., Gallardo E., Garc R., Guix M., Laínez N., Marino A., Montesa Á., Pinto A., Puente J., Romero G., Suárez C., Virizuela J. (Expert Review Of Anticancer Therapy, 2017)